David Roife
YOU?
Author Swipe
View article: Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma Open
This table summarizes the dose (multiplicity of infection, MOI) of Delta-24-RGD that causes 50% of viability inhibition of infected pancreatic cancer cell lines (IC50).
View article: Data from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Data from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma Open
Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In a phase I clinical trial, Delta-24-RGD has shown favor…
View article: Data from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Data from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma Open
Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In a phase I clinical trial, Delta-24-RGD has shown favor…
View article: Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma Open
This table summarizes the dose (multiplicity of infection, MOI) of Delta-24-RGD that causes 50% of viability inhibition of infected pancreatic cancer cell lines (IC50).
View article: Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
HPaSteC and Media: Western blot and ELISA assay: Vectra Automated Quantitative Pathology Imaging System (VAQPIS, PerkinElmer): Double Immunofluorescence staining (IF), and Vectra multispectral analysis: Supplementary figure legends:
View article: Supplementary Methods from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Methods from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Clinical Correlation Studies, Tissue Microarray and Statistical Analysis.
View article: Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Supplementary Table 1. Wild type and mutant lumican SBE oligos for EMSA. Supplementary Table 2. Clinicopathologic and oncologic outcome correlation of stromal lumican expression in PDAC. Supplementary Table 3. Amount of Lumican Secretion i…
View article: Supplementary figure 4 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 4 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
PDAC cells matrix adhesions were affect by HPSC supernatant of 24 hour's collection.
View article: Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Vectra Image analysis workflow, Double IF staining of lumican and collagen I, and TGF-β secretion in HPSC.
View article: Supplemental Methods and Supplemental Figure 1 Legend from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Supplemental Methods and Supplemental Figure 1 Legend from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Supplemental Materials and Methods: Immunohistochemical staining of cleaved caspase 3, statistical analysis of the correlation of LTSA values with patients' progression free survival; Supplemental Figure legend
View article: Data from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Data from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Purpose: Translation of the patient-derived xenograft (PDX) model into a method for practical personalized cancer treatment is prevented by the intense resources and time necessary to generate and test each tumorgraft. We aimed to develop …
View article: Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Univariate analysis of factors associated with overall survival, recurrence-free survival, and liver-specific recurrence-free survival.
View article: Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Lumican expression and secretion in HPaSteC with or without TGF-β exposure at 8 and 24 hours.
View article: Supplementary Figure 1 from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure 1 from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Tissue slices after treatment with Gemcitabine (100 µM) or Irinotecan (30 µM) for 48 hours were fixed and embedded for immunohistochemical staining of cleaved-Caspase 3 (40X magnification, Bars = 20 µm).
View article: Data from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Data from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Purpose: To evaluate the relevance between lumican expression patterns and the clinical course of patients with pancreatic ductal adenocarcinoma (PDAC), and to investigate the role of lumican in PDAC progression.Experimental Design: One hu…
View article: Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Vectra Image analysis workflow, Double IF staining of lumican and collagen I, and TGF-β secretion in HPSC.
View article: Supplemental Methods and Supplemental Figure 1 Legend from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Supplemental Methods and Supplemental Figure 1 Legend from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Supplemental Materials and Methods: Immunohistochemical staining of cleaved caspase 3, statistical analysis of the correlation of LTSA values with patients' progression free survival; Supplemental Figure legend
View article: Data from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Data from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Purpose: To evaluate the relevance between lumican expression patterns and the clinical course of patients with pancreatic ductal adenocarcinoma (PDAC), and to investigate the role of lumican in PDAC progression.Experimental Design: One hu…
View article: Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Univariate analysis of factors associated with overall survival, recurrence-free survival, and liver-specific recurrence-free survival.
View article: Supplementary Figure 1 from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure 1 from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Tissue slices after treatment with Gemcitabine (100 µM) or Irinotecan (30 µM) for 48 hours were fixed and embedded for immunohistochemical staining of cleaved-Caspase 3 (40X magnification, Bars = 20 µm).
View article: Data from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Data from <i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Open
Purpose: Translation of the patient-derived xenograft (PDX) model into a method for practical personalized cancer treatment is prevented by the intense resources and time necessary to generate and test each tumorgraft. We aimed to develop …
View article: Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Clinicopathologic and oncologic outcome correlation of lumican expression subgroups.
View article: Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Supplementary Table 1. Wild type and mutant lumican SBE oligos for EMSA. Supplementary Table 2. Clinicopathologic and oncologic outcome correlation of stromal lumican expression in PDAC. Supplementary Table 3. Amount of Lumican Secretion i…
View article: Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
HPaSteC and Media: Western blot and ELISA assay: Vectra Automated Quantitative Pathology Imaging System (VAQPIS, PerkinElmer): Double Immunofluorescence staining (IF), and Vectra multispectral analysis: Supplementary figure legends:
View article: Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Clinicopathologic and oncologic outcome correlation of lumican expression subgroups.
View article: Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Multivariate Analysis of Factors Associated with Overall Survival, Recurrence-Free Survival, and Liver-Specific Recurrence-Free Survival.
View article: Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery Open
Multivariate Analysis of Factors Associated with Overall Survival, Recurrence-Free Survival, and Liver-Specific Recurrence-Free Survival.
View article: Supplementary figure 3 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 3 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Lumican secretion associated with cell matrix migration.
View article: Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Open
Lumican expression and secretion in HPaSteC with or without TGF-β exposure at 8 and 24 hours.